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Background: Women who carry a mutation for Lynch syndrome face complex decisions regarding strategies for
managing their increased cancer risks. At present, there is limited understanding of the factors influencing women’s
prophylactic surgery decisions.
Methods: As part of an exploratory pilot project, semi-structured interviews were conducted with 10 women who
were Lynch syndrome mutation carriers and had made prophylactic surgery decisions. Nine of 10 women had
chosen to undergo prophylactic hysterectomy and/or oophorectomy as a means of managing their increased
gynecological cancer risks.
Results: Study findings revealed that surgery decisions were influenced by multiple factors, including demographic
variables such as age and parity, as well as psychosocial factors such as cancer worry, in addition to personal
and social knowledge of gynecological cancer. While all women were satisfied with their surgery decision,
some reported they were not fully informed about the negative impact on their quality of life post-surgery
(e.g., complications of surgically-induced menopause), nor about the potential for, or risks and benefits of, hormone
replacement therapy.
Conclusions: Study findings highlight some of the factors associated with prophylactic surgery decisions and
women’s perceptions about pre-surgical information provision and needs. Suggestions are made for improving the
information and support provided to female carriers of a Lynch syndrome mutation.
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Hereditary non-polyposis colorectal cancer (HNPCC) or
Lynch sndrome (LS), accounts for 3-5% of all colorectal
cancers [1,2]. It is a dominantly inherited syndrome, pre-
disposing carriers to a high risk of early-onset colorectal
cancer [1-5]. LS is caused by mutations in four mis-
match repair genes: MLH1, MSH2, MSH6, and PMS2
[1]. In addition to their increased colon cancer risk,
women carrying these germline mutations have dramat-
ically elevated rates of gynecological cancer compared to
women in the general population. They face a 40-60%* Correspondence: holly.etchegary@med.mun.ca
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unless otherwise stated.lifetime risk of endometrial cancer and a 10-12% lifetime
risk of ovarian cancer, compared to the general popula-
tion risks of ~3% and ~1.4%, respectively [1-3].
Currently, women at increased hereditary risk for
gynecologic cancers have two risk management options:
1) increased cancer surveillance, or 2) surgical removal
of the uterus (hysterectomy) and/or removal of the ovar-
ies and the fallopian tubes known as risk-reducing
salpingo-oophorectomy (RRSO). Since some Lynch-
associated cancers are diagnosed before the age of 35,
some authors recommend annual surveillance in this
high-risk group of mutation carriers, including transva-
ginal ultrasonography, tumor marker CA125 blood tests
and/or endometrial biopsy [6,7]. At present, however,
the benefit of screening for gynecological cancers in
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ing modality or timing [8]. In our jurisdiction, we found
that screening did not result in earlier gynecologic can-
cer detection in mutation carriers, and despite screening,
two young women died from ovarian cancer [9]. In
contrast, prophylactic gynecological surgery (RRSO
and/or hysterectomy) significantly reduces the risk of
gynecological cancers. Schmeler and colleagues [10]
reported that none of 61 women with LS were diagnosed
with endometrial cancer after prophylactic hysterectomy,
compared to 33% of women who had not undergone
surgery. Lacking evidence for the effectiveness of
gynecological cancer screening, it is generally recom-
mended that females with LS consider prophylactic
hysterectomy with RRSO upon the completion of child-
bearing since these procedures largely prevent the devel-
opment of endometrial and ovarian cancers [7-11].
While an extensive literature exists regarding the up-
take of prophylactic gynecological surgery in women car-
rying hereditary breast/ovarian cancer mutations (BRCA
1 and BRCA 2), fewer studies examined the surgical de-
cisions of the female LS population. Research with
women carrying BRCA mutations reveals that demo-
graphics (e.g., older age, having children), medical fac-
tors (e.g., personal or family history of breast and
ovarian cancer), and psychosocial factors (e.g., high
levels of cancer worry) are positively correlated with
RRSO uptake [12-14]. Most women are satisfied with
their surgery decisions, and report lower levels of per-
ceived cancer worry, and higher levels of control follow-
ing surgery [14]. Premenopausal women reported the
most negative impacts following surgery [12,13]. These
included negative physical effects, such as hot flashes,
vaginal dryness, reduced sexual interest and pleasure,
and pain during intercourse. The literature is mixed re-
garding satisfaction with information received prior to
surgery: some women felt they were fully informed,
while others did not have enough information to make
decisions about hormone replacement therapy [13-15].
Overall, however, the rate of satisfaction with prophylac-
tic gynecological surgery in women with BRCA muta-
tions is very high [12-15].
Considerably fewer studies focused on prophylactic
surgery decisions in female LS mutation carriers. How-
ever, research suggests that women affected by LS may
not understand the complexity of the diagnosis, at least
prior to genetic counseling. A survey study of 65 women
reported low awareness of extra-colonic cancers and de-
creased use of endometrial screening before genetic
counseling [16]. A small qualitative study involving
women at risk for familial ovarian cancer (due to family
history, not Lynch syndrome) reported gaps in know-
ledge about ovarian cancer screening and prophylactic
oophorectomy [15]. The authors suggested such gapsraised concerns about the extent to which women were
making informed cancer risk-management decisions.
They identified several areas where the provision of in-
formation could be improved, including practical details
about the operation itself and postoperative function-
ing, as well as the risks and benefits of hormone re-
placement therapy. Compared to women carrying
BRCA mutations, the risks associated with the use of
HRT (e.g., increased risk of breast and endometrial
cancer) are lower for women affected with Lynch syn-
drome [7,12].
A recent study reported that LS carriers were compli-
ant with guidelines for cancer risk reduction in the year
following genetic testing, with nearly 70% opting for
prophylactic hysterectomy by three-year follow up [17].
Research suggests prophylactic surgery decisions are
complex, driven by demographics (e.g., age, parity), medical
factors (e.g., mutation status or abnormal ovarian screening
results) and psychosocial factors (e.g., anxiety about cancer
risk) [14-18]. Ovarian screen-detected abnormalities
(e.g., cysts) were often sufficient motivation for women
to discontinue screening and opt for surgery, as was the
advice of clinicians [18]. A recent study of 74 women
with LS [19] found the majority were knowledgeable
about aspects of gynecological screening (e.g., age at
which to begin) and had accurate perceptions of their
colorectal and endometrial cancer risks. However, half
reported that their care providers did not inform them
about gynecologic cancer screening recommendations,
and about half of the women were not adherent to
screening guidelines. Providers’ knowledge (including
family physicians and oncologists) was a key factor in
determining appropriate risk management strategies for
female LS carriers, and those who did not perceive their
providers as knowledgeable were less likely to engage in
appropriate screening [20].
The factors underlying prophylactic surgical decisions
in female LS mutation carriers are not well understood,
nor is there sufficient evidence to assess whether women
are making informed decisions [18-21]. Research is
needed to determine the best model to educate women
about their risks and options. This study aims to con-
tribute to the evidence base by soliciting the opinions of
women affected by LS about their risk-management de-
cisions and experiences.
Methods
This was an exploratory pilot project designed to investi-
gate the surgical decisions of female LS mutation car-
riers. Guided by these results, future research will
administer a survey to the larger population of women
who have made surgical decisions in our jurisdiction.
The project was approved by the local Health Research
Ethics Authority (HREA).
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In Newfoundland and Labrador (NL), Canada, the
gynecologic oncology service is located at the Health
Sciences Centre (HSC) in the capital city of St. John’s, NL.
Women can be referred through their family physicians or
other specialists (e.g., oncologists, obstetricians) who note
a strong family history of gynecological cancer. Women
may also be referred to this speciality service through
the Provincial Medical Genetics Program (PMGP), the
province-wide genetics service, also located at the HSC in
St. John’s.
The PMGP, as well as the gynecological oncology ser-
vice, maintains a Provincial Cancer Genetics database of
all women affected by inherited cancers in the province.
Women affected by LS who had undergone prophylactic
gynecological surgery within the previous five years were
identified through this database. We also searched for
female carriers of LS who chose not to have surgery,
and identified one who could participate during the re-
cruitment period. Women were purposively sampled to
provide a breadth of experience with surgery decisions
(e.g., those who lived in rural and urban areas, of differ-
ent ages, and those for whom varying amounts of time
had passed since surgery). These women were con-
tacted by telephone by their physician and asked to call
the research team if they were interested in participat-
ing. In total, 14 potential participants were approached
with ten eventually completing an interview. Time con-
straints during the data collection period precluded
four women from participating. Consent was obtained
via post before the interview, and verbal consent at the
interview.
The interviews
Interviews were conducted by telephone between April
2012 and June 2013 by HE and ED. Since most partici-
pants lived outside the study area, telephone interviews
were chosen as the most convenient by all participants.
With permission, interviews were tape-recorded and
transcribed verbatim. Interviews lasted from approxi-
mately 30 min to 1 hour. A detailed question guide facil-
itated the tracking of all questions asked during each
interview, and women were encouraged to discuss other
issues they felt were important. Interviews covered a
core set of topics such as family experience of cancer,
genetic testing and surgery decisions, impact of the sur-
gery and information needs.
Data analysis
Qualitative description [22] was used to explore and
summarize women’s surgery decisions. This is a form of
naturalistic inquiry that makes no a priori theoretical or
philosophical assumptions about the data. Rather, it
seeks to present the data in the language of participants,without aiming to present the data in more theoretical
ways. The end result is a comprehensive summary of the
event in question [22].
Transcripts were read and re-read several times by
HE. Data were then isolated and organized around
interview topics; only data pertaining to surgery deci-
sions were utilized for the current analysis. These sec-
tions were read and re-read to identify and index
emerging categories and themes, which were anno-
tated on the transcripts. No qualitative software was
used in the analysis. Inductive subcoding of the data
relevant to surgery decisions and information needs
was completed using the method of constant compari-
son [23,24]. Here, data were compared between and
within transcripts to establish analytical categories and
themes [23]. This method required a constant shifting
back and forth between (and within) transcripts to
continuously compare the perceptions and experiences
of participants. Discussion with a second investigator
(ED) throughout the analysis verified emerging cat-
egories and themes until no new themes could be
added. Thematic findings were then discussed with the
larger research team. No new categories or themes
were suggested after team discussion, and data satur-
ation was deemed complete.
Results
Participants
Of the 14 women approached for the study, ten eventu-
ally completed an interview. The four non-respondents
were not different from the included sample in age
range, family history of cancer or surgery decision (e.g.,
all had undergone prophylactic gynecological surgery).
Thus we have no reason to believe their exclusion biased
the results. Ten participating women ranged from 33–64
years, with a mean age of 49 years. Nearly all had a part-
ner and had adult children. All women were LS muta-
tion carriers, with nine choosing prophylactic surgery.
An average of about three and a half years had passed
since the time of their surgery, though this was variable
(Range: 6 weeks to 8 years). Most women had had
prophylactic hysterectomy, as well as oophorectomy
(Table 1).
Study findings are organized around two key themes:
1) prophylactic gynecological surgery decisions, and
2) information provision and needs (Table 2). Most
women did not describe their choice of surgery as a
‘decision,’ but something that had to be done. Several
interacting factors seemed to underlie this perception,
including personal history of cancer and/or a history of
abnormal gynecological events (e.g., menstrual issues;
ovarian cysts), as well as empathetic knowledge of
others’ cancer experiences. These factors created a high
level of worry about cancer, and surgery was seen as a
Table 1 Demographic and clinical information of interview participants
Participant Current age Age at surgery Mutation Year of
surgery
Type of surgery Prior cancer? Use of hormone
replacement therapy?
Sue 52 48 MSH2 2009 Total abdominal hysterectomy and
bilateral salpingo-oophorectomy
Yes, colon No
Mavis 45 41 MSH2 2010 Laproscopic assisted vaginal
hysterectomy and bilateral
salpingo-oophorectomy
No Yes
Delores 58 55 MLH1 2010 Laproscopic assisted vaginal
hysterectomy and bilateral
salpingo-oophorectomy
No Intermittent use
Cheryl 52 44 MSH2 2005 Laproscopic assisted vaginal
hysterectomy and bilateral
salpingo-oophorectomy
No Yes
Linda 33 33 MSH2 2013 Laproscopic assisted vaginal
hysterectomy and bilateral
salpingo-oophorectomy
No Yes
Tonya 37 Decided against
surgery
MSH2 N/A N/A No N/A
Laura 64 61 MSH6 2010 Laproscopic assisted vaginal
hysterectomy and bilateral
salpingo-oophorectomy
Yes, colon and breast No
Madonna 57 56 MSH2 2012 Laparoscopic Right oophorectomy No No
Andrea 45 44 MSH6 2011 Laproscopic assisted vaginal
hysterectomy and bilateral
salpingo-oophorectomy
No No
Erin 49 42 MSH2 2006 Total abdominal hysterectomy and
bilateral salpingo -oophorectomy
No No
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mendation, along with demographic factors, also influ-
enced surgery decisions. Often, a combination of these
factors seemed to influence decisions, as revealed in the
narratives below.Table 2 Main themes and subthemes arising from
interview data
Main themes Subthemes
1. Factors associated with
prophylactic gynecological
surgery decisions
Wanting to mitigate cancer worry
Empathetic knowledge of others’
cancer experiences
Physician recommendation
Demographic factors such as age
and parity
2. Information provision
and needs
Feeling adequately informed prior
to surgery
Needing time to process
information prior to surgery
Information needs, including the
sudden onset of surgical-induced
menopausal symptoms and the
risk and benefits of hormone
replacement therapyProphylactic gynecological surgery decisions
Mitigating cancer worry
A personal or strong family history with cancer or a
history of abnormal gynecological events influenced
women’s surgery decisions.
I can make decisions like that pretty quick when it
comes to cancer. To cut out anything as long as there
is not any cancer there. -Laura, 64 yrs, 2 prior cancers
I was bleeding all the time, my womb was full of
fibroids, my ovaries were enlarged…so it probably
would have developed into something. -Sue, 52 yrs,
prior cancer
With a strong family history of cancer, Linda
described the motivation behind her surgery decision
simply, “Take that worry off my plate. It has to go.”
Empathetic knowledge
Knowledge of the cancer experiences of others seemed
to propel some participants in deciding to undergo
prophylactic surgery. Linda recalled:
…one of my friends was just diagnosed with ovarian
cancer…she’s not doing too good…seeing her and
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sudden, she had these big tumors. It happened to her
so quick, it could happen to me that quick too. -Linda,
33 yrs, no prior cancer
Similarly, Madonna explained:
And here was my friend going through ovarian cancer;
she died a month and a half ago. That kind of put the
top on it for me. -Madonna, 57 yrs, no prior cancer
Physician recommendation
The advice of physicians also influenced women’s
surgical decisions:
He [family doctor] made sure I was getting tested for
everything. And the doctors in there [cancer clinic]
did mention it, because Mom had had cancer a
couple of times, I could have the hysterectomy and
at least that way, I’d be safe. –Erin, 49 yrs, no
prior cancer
Her strong family history of cancer, coupled with ab-
normal periods, prompted her physician to recommend
prophylactic surgery:
I was having a real lot of trouble with my periods, and
a lot of pain…He told me that more than likely, by the
time I was 45, I should have the hysterectomy done
anyway. So that just helped me along to decide to
have it earlier than later.
Sue also discussed her options with her family
physician:
So I used to go back to my family doctor, and he said,
‘with your risk of cancer, have you considered having
everything taken out?’And I said, ‘Yes, because of the
cancer, and I can’t go on like this. –Sue, 52 yrs,
prior cancer
Demographic factors – age and childbearing considerations
Mavis explained that her childbearing was complete:
I wanted one child, and that was it. I knew I was done
having children. ..I was a little concerned about losing
my ovaries and uterus at the time, but I thought it
was probably the best thing to do. –Mavis, 45 yrs, no
prior cancer
Andrea recalled:
And with me having the gene and talking about
hysterectomy, and I said, ‘take it out.’ I don’t have anychildren, I don’t want any children…that’s the only
purpose for it to be there. I said, ‘so I want it taken
out.’ –Andrea, 45 years, no prior cancer
The lone participant who decided to engage in in-
tensive screening, rather than prophylactic surgery
explained:
It’s a lot to take in. I’m only 37 years old…I’m still
young…to go through a surgery and put yourself in
early menopause? I don’t know. There’s a lot to think
about. I mean, there were other alternatives. –Tonya,
37 yrs, no prior cancer
These narratives suggest that women’s surgical deci-
sions were driven by complex interactions of personal,
social and medical factors. No woman described her de-
cision as particularly difficult; all expressed the sense
that there was little choice given their personal risk for
gynecological cancer. Further, no woman expressed re-
gret about having had surgery. All explained the surgery
helped alleviate the fear of developing a gynecological
cancer. However, it is not meant to suggest that these
decisions were somehow ‘easy’ for women. As Cheryl
recalled:
I was in my early 40s, and I’m going to have my
uterus, my cervix and ovaries taken out and
they’re healthy right now? And I’m not having any
gynecological issues at all. That’s major surgery.
I’m off work for six weeks. I had a toddler at
home that I couldn’t pick up. I go right into
surgical menopause. We’re not that long married,
and there are issues around sexual response. All
those things go through your mind. –Cheryl,
52 yrs, no prior cancer
Information provision and needs
Feeling informed
Most women reported they had received enough infor-
mation to make informed surgery decisions and were
satisfied with the care they received.
I think I was really well prepared going into the
surgery…[surgeon] was telling me all the risks and all
the benefits. –Linda, 33 yrs, no prior cancer
Similarly, Delores explained:
I had an idea of what I wanted to do if the option
was available to me, you know, partial versus full
[hysterectomy]. I also did a lot of reading and
even looked up the surgery itself, so I knew what
to expect. –Delores, 58 yrs, no prior cancer
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as screening and surgery options, Andrea simply said:
Oh yes, she went through all that. I understood what
she was saying. –Andrea, 45 yrs, no prior cancer
Needing time to process information
Despite feeling they had made informed surgical decisions,
women noted the complexity of the information and sug-
gested time was needed to fully process their options.
It was pretty overwhelming at the time…my actual
meeting with the genetic counselors when I got
my results back is a blur. I don’t remember in any
detail what was said to me, but I was given
written material. I was able to later read all of that
thoroughly and understand it. –Cheryl, 52 yrs, no
prior cancer
[genetic counselor] had given me a lot of information,
and until you go home and look at it, you don’t really
take it all in. …but she’s [gynecologist] been very
informative, and she’s been talking to me about it
[surgery]. –Tonya, 37, no surgery, no prior cancer
Information needs
Study findings reveal gaps in information provided to
women who undergo prophylactic gynecological sur-
gery. The potential implications of surgically-induced
menopause, as well as the severity of symptoms were
mentioned by several women. Some also noted they
were unaware of the possibility of hormone replace-
ment therapy.
I didn’t feel I had enough information, no. I think I
should have been more informed about the hot
flashes and stuff about the sexual drive. –Sue, 52 yrs,
prior cancer
When asked if she had discussed surgically-induced
menopause with care providers prior to surgery, Erin
said:
I don’t think so. I’m not sure if anyone did or not. –Erin,
49 yrs, no prior cancer
Many women also could not recall discussing hormone
replacement therapy:
No, not that I can recall. –Madonna, 57 yrs, no prior
cancer
No, that was never mentioned. –Laura, 64 yrs, 2 prior
cancersWhen this subject is bought up to a woman getting a
hysterectomy, there needs to be some more
information about the hormone replacements that
are available…even something that was printed
about the best options or what’s out there to be
handed out. –Mavis, 45 yrs, no prior cancer
Discussion
Findings reveal that surgical decisions are complex,
driven by interacting demographic, medical and psycho-
social variables. Most women recalled no ‘choice’ about
surgery, due to their high risk for gynecological cancer
and need to reduce levels of cancer worry. Findings sup-
port the larger BRCA literature which suggests reducing
cancer worry is a key motivator of prophylactic sur-
gical decisions [12,13]. Women noted other influences
on their decisions, including abnormal gynecological
screening results, the advice of healthcare providers, and
demographic variables. Abnormal gynecological screening
results can prompt further risk-management discussions
with healthcare providers about surgery, rather than have a
negative psychosocial impact on women [18]. No woman
in our study reported feeling pressure from providers to
choose surgery, and results suggest that regular appoint-
ments with clinicians to discuss risk-management options
would be well tolerated rather than waiting until an abnor-
mal screening test initiates the discussion.
In line with previous research [13,18], considerations
such as the completeness of childbearing and age also
influenced surgery decisions. Findings highlight the im-
portance of timing in the decision to have prophylactic
surgery and the need to re-visit screening vs. surgery de-
cisions in the presence of changing personal circum-
stances. Knowledge of others’ cancer may also affect
women’s surgical decisions. Some women explained how
seeing friends affected with ovarian cancer contributed
to their decision. We have previously described this in-
fluence on prenatal screening decisions as ‘empathetic
knowledge,’ or subjective knowledge arising from close
associations with others [25]. Through empathetic
knowledge, women may give meaning to their own can-
cer risk or decide that the timing is right for surgery. In
the experiential knowledge framework, knowledge pro-
duction is not static and may be revised at any time in
response to new experiences and relationships [25,26].
We suggest this knowledge may be an important influ-
ence on cancer risk perception and worry, and can im-
pact risk-management decisions. An exploration of
women’s social knowledge may help assess whether
there are any misunderstandings or information gaps.
d’Agincourt-Canning [27] suggested that genetic coun-
selors probe more deeply their clients’ experiences and
corresponding experiential knowledge. She suggested
that in addition to collecting family history information,
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riences or perceptions of cancer’s survivability in order
to better understand women’s risk perception. Such
discussions may also be valuable in understanding LS
carriers’ perceptions of their cancer risks and risk-
management options in order to promote informed sur-
gical decision-making.
Most women did feel informed to make surgical deci-
sions; although, some noted that adequate time was
needed outside the clinic to process the vast amount of
information provided. While most women were satisfied
with the information they received, some gaps were
noted, such as the severity of surgically-induced meno-
pausal symptoms and the availability of hormone re-
placement therapy. A minority of women recalled that
while they were aware of surgically-induced menopause,
they did not appreciate its speed of onset and potential
intensity. These findings are in line with recent research
[28], which reported nearly 60% of women who had
undergone prophylactic oophorectomy would have liked
more information about the impact of the surgery on
their sex lives. These findings and ours suggest that
while many women are well informed about surgically-
induced menopause, it is apparent that not all appreciate
how quickly menopause can set in following surgery,
nor the effect it can have on their sexual relationships.
Thus, women should be encouraged to carefully con-
sider the impact surgery can have on their sexuality and
be provided with proactive strategies to facilitate sexual
adjustment in the event of difficulty [13,28].
Women should also be given information about the
risks and benefits of hormone replacement therapy
(HRT), though evidence suggests they may not be given
adequate information in this regard [15]. Of course, clin-
ical judgement will be necessary in discussions about
HRT. In our sample, some women were in their 50s and
60s at the time of their surgery and their older age could
have affected whether discussions were held about HRT.
While several women in our study either could not re-
call being given such information or said they did not re-
ceive it, research suggests women at increased risk for
ovarian cancer want as much information as possible
about their risk-management options, and our findings
corroborate these earlier studies [15,21]. We note that
no women in our study suggested she would have
chosen differently or that a lack of information somehow
impeded her surgery decision. Nonetheless, they did
highlight some areas where additional information could
be provided, and we hope this is useful information
for providers who are caring for women with Lynch
syndrome.
Finally, given these information needs and the finding
that physician recommendation was a motivating factor
for surgery, study findings suggest that awareness of LScancer risks and management guidelines can be im-
proved among providers, including family physicians
and oncologists [19,20]. This is consistent with other
studies observing limitations in providers’ knowledge
and management of hereditary cancer syndromes [20,26].
Like others [19,20], we suggest that continued efforts to
educate providers about screening recommendations
for high-risk patients is an important focus for future
research.
Conclusions
This small pilot study revealed motivations behind the
prophylactic surgical decisions of women affected with
LS, as well as their perceptions about pre-surgical infor-
mation provision and needs. However, some study limi-
tations are noted. The sample size is very small, and the
study was conducted in a comprehensive cancer service;
findings may not generalize to patients seen outside such
centres. Further, we could only recruit one patient who
declined surgery and opted for surveillance instead, and
as such, findings cannot be generalized to women de-
clining surgery. Data rely on patient recollection of pre
and post-surgical discussions with providers. We did not
collect data on the content of these discussions, and the
data may suffer from recall bias. Despite these limita-
tions, study findings are in line with the growing litera-
ture on LS carriers and highlight areas for discussion in
risk-management counseling and implications for infor-
mation provision regarding prophylactic surgery.
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